Oncology Exchange
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting
Breast Cancer - Emerging Agents in Her2-postitive Breast Cancer
Emerging Strategies for the Management of Recurrent Ovarian Cancer
Non-Hodgkin's Lymphoma - Emerging Agents in Relapse/Refactory Non-Hodgkin's Lymphoma
Gastrointestinal Stromal Tumors - Emerging Multidisciplinary Approaches for the Management of Gastrointestinal Stromal Tumors
Challenges in Treating Renal Cell Carcinoma in the Community
Current Treatment Strategies for Chronic Myelogenous Leukemia
Personalizing Treatment for NSCLC An Oncology Exchange Program
Evidence-based Management of Metastatic Colorectal Cancer
Evolving Treatment Strategies for Mantle Cell Lymphoma in Elderly Patients
Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
Rockpointe.com The confluence of medical science and clinical need

Oncology Exchange:
Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting

A series of Live Grand Rounds Programs, Chapter Meetings, and an On-demand CME-certified Webcourse.

Welcome to "Oncology Exchange: Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting.” This CME-certified initiative is intended for community-based hematologists/oncologists, oncology nurses, NPs, APNs, and other clinicians involved in the care of patients with multiple myeloma (MM). A series of live CME-certified programs will be presented at selected hospitals and ASCO State/Regional meetings throughout the US during 2015, and an online CME-certified webcourse will be available later in 2015.

Program Description

Community hematologists and oncologists are constantly challenged to stay up to date with advances in the management of MM. Updates are needed on the role of cytogenetic and molecular analyses to personalize treatments for MM, along with guidance on the optimal use of induction therapy, transplants, and novel agents to help improve patient survival.

Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting is designed to help clinicians understand the new and emerging therapeutic options in MM, and will also provide guidance on the optimal treatment strategy to manage smoldering myeloma.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement:

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email contact@potomacme.org.

Calendars for Live Activities

Back to Top

Visiting Professor Series

Chapter Meetings

Related Online Offerings

Back to Top

Additional CME/CE-certified Oncology Exchange programming can be found at: http://www.medscape.org/sites/advances/oncologyexchange.

Live Program Materials for Speakers and Administrators

Back to Top

I. Administrator Material

II. Speaker Material

Audio Orientation

Thank you for joining us as an expert speaker for the Visiting Professor Series, "Oncology Exchange: Frequently Asked Questions Regarding the Management of Multiple Myeloma in the Community Setting."

This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:

  • Discuss the role of cytogenetic and molecular analyses in personalizing care in MM
  • Review the treatment course for patients with smoldering MM
  • Assess the optimal use of induction therapy and transplant to improve patient survival in MM
  • Evaluate the use of high-dose chemotherapy vs novel agents for relapsed/refractory MM

Transcript of Speaker Orientation Download (PDF)

Audio download of Speaker Orientation

Audio Download

CME-certified Program Slides

In an effort to provide timely clinical information, the curriculum for this activity was updated by the steering committee to include data that was recently published and/or presented at key oncology conferences, such as the 2015 annual meetings of the American Society of Hematology and the American Society of Clinical Oncology. The updated slide deck containing those slides are now available here. Download (PowerPoint)

Steering Committee and Speaker Biographies

Back to Top

Ajai Chari, MD
Associate Professor of Medicine
Director of Clinical Research, Multiple Myeloma Program
Icahn School of Medicine
Mount Sinai Hospital
New York, NY

Ajai Chari, MD previously served as an Assistant Professor of Medicine at the Columbia University College of Physicians and Surgeons, where he founded and developed the Multiple Myeloma Program and was a member of the Stem Cell Transplant Program. He then joined the Myeloma Program at St. Vincent's Comprehensive Cancer Center, prior to its transition to the Mount Sinai Medical Center. The Plasma Cell Disorders Program at Mount Sinai is nationally renowned for its clinical and research excellence. With a high patient volume, the program has a robust clinical trials portfolio consisting of investigator-initiated, Multiple Myeloma Research Consortium-sponsored, and industry-sponsored phase I and II studies.

With a longstanding dedication to research, Dr. Chari has received various research fellowships, has published numerous articles in the field, has served as an American Society of Hematology moderator and abstract reviewer, and is the Principal Investigator on many clinical trials. He has also given numerous lectures on plasma cell disorders and has received awards for excellence in housestaff teaching.

Sergio Giralt, MDSergio Giralt, MD
Chief, Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Sergio Giralt, MD is the Chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York, NY. He is also affiliated with Weill Cornell Medical College as a Professor of Medicine. He received his medical degree from Universidad Central de Venezuela in Caracas, Venezuela, and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, OH and a postdoctoral fellowship in hematology and oncology at the University of Texas MD Anderson Cancer Center.

Board-certified in internal medicine, hematology, and medical oncology, Dr. Giralt holds membership in several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation, and International Society of Haematology. He holds key positions with several organizations, including the International Bone Marrow Transplant Registry Executive Committee, the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) Steering Committee, the National Marrow Donor Program Board of Directors, and the Clinical Advisory Board of the Website Managing Myeloma.

Dr. Giralt is the President-elect of the American Society for Blood and Marrow Transplantation, as well as the Past Chair of the BMTCTN and of the Center for International Blood and Marrow Transplant Research.

Dr. Giralt has published more than 400 articles and abstracts in the peer-reviewed literature and has written chapters for several books. In addition, Dr. Giralt is a reviewer and editorial board member for several journals.

Back to Top
This CME-certified activity is jointly provided by Potomac Center for Medical Education and Rockpointe Oncology.
This activity is supported by unrestricted educational grants from Celgene Corporation and Takeda Oncology.
©2015 PCME